Literature DB >> 15615248

[Vasculitis associated with viral infections].

Pascal Cohen1, Loïc Guillevin.   

Abstract

VIRUSES, THE CAUSE OF VASCULITIS: Although the majority of systemic vasculitis are of unknown causes, the responsibility of a viral infection has been formally demonstrated in some of them and specific treatment can permanently cure them. Each virus incriminated accounts for a particular type of vasculitis. HEPATITIS B VIRAL INFECTION (HBV): Is the cause of polyarteritis nodosa in 36 to 50% of cases. The onset of the symptomatology is acute, usually within a few months following the infection; it is comparable to that observed in the absence of HBV infection. CRYOGLOBULINEMIA RELATED TO THE HEPATITIS C VIRUS (HCV): The clinical manifestations are those of systemic vasculitis with particular tropism for the skin (involvement generally inaugural and almost constant), peripheral nerves and the glomerula. They occur fairly late during the infection. VASCULITIS ASSOCIATED WITH HIV INFECTION: There is strong tropism for the peripheral (multi-neuritis) and central nervous system. During acute parvovirus B19 infection Vasculitis lesions have occasionally been reported following the viremic phase, generally limited to one or several flares of vascular purpura predominating on the lower limbs. FOLLOWING VARICELLA-HERPES ZOSTER INFECTION: Vasculitis occasionally develops in the form of a central neurological deficiency (locomotor deficiency with or without aphasia around one month after an ophthalmologic herpes zoster) or involving the retina or, more rarely, the skin or the kidneys. VASCULITIS ASSOCIATED WITH CYTOMEGALOVIRAL INFECTION: Predominantly observed in immunodepressed patients, vasculitis after CMV infection is diffuse and basically involving the digestive tube, notably the colon, the central nervous system and the skin. A RARE COMPLICATION OF AN HTLV1 INFECTION: Vasculitis of the retina often in the form of necrotic retinitis is often associated with spasmodic paraparessia. THERAPEUTIC STRATEGY: For many vasculitis of viral origin, corticosteroid and immunosuppressive treatments are only indicated in second intention following failure with antiviral agents and the combination of antivirals and plasma exchanges.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15615248      PMCID: PMC7135323          DOI: 10.1016/s0755-4982(04)98936-1

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  215 in total

1.  Glomerulonephritis and Henoch-Schoenlein purpura associated with acute parvovirus B19 infection.

Authors:  F Díaz; J Collazos
Journal:  Clin Nephrol       Date:  2000-03       Impact factor: 0.975

2.  [Sicca syndrome and hepatitis C virus infection: a Gougerot-Sjögren pseudo-syndrome?].

Authors:  A Boscagli; P Y Hatron; V Canva-Delcambre; E Hachulla; A Janin; C Paris; B Devulder
Journal:  Rev Med Interne       Date:  1996       Impact factor: 0.728

3.  Adult Still's disease associated with acute human parvovirus B19 infection.

Authors:  J Pouchot; H Ouakil; M L Debin; P Vinceneux
Journal:  Lancet       Date:  1993-05-15       Impact factor: 79.321

4.  Henoch-Schönlein purpura and human parvovirus B19.

Authors:  S Veraldi; G Rizzitelli
Journal:  Dermatology       Date:  1994       Impact factor: 5.366

5.  Cytomegalovirus infection in systemic necrotizing vasculitis: causative agent or opportunistic infection?

Authors:  M F Meyer; B Hellmich; S Kotterba; H Schatz
Journal:  Rheumatol Int       Date:  2000-12       Impact factor: 2.631

6.  [Rheumatoid purpura in adults and parvovirus B19 infection: fortuitous association or parvovirus B19-induced vasculitis?].

Authors:  T Quéméneur; M Lambert; A L Fauchais; V Queyrel; U Michon-Pasturel; E Hachulla; P Y Hatron; B Devulder
Journal:  Rev Med Interne       Date:  2002-01       Impact factor: 0.728

7.  Cutaneous and systemic necrotizing vasculitis in swine.

Authors:  S Thibault; R Drolet; M C Germain; S D'Allaire; R Larochelle; R Magar
Journal:  Vet Pathol       Date:  1998-03       Impact factor: 2.221

8.  Detection of varicella zoster virus DNA in some patients with giant cell arteritis.

Authors:  B M Mitchell; R L Font
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-10       Impact factor: 4.799

9.  [Red fingers syndrome in the course of HIV infection. A new case].

Authors:  G Lair; H Levesque; F Lecomte; N Cailleux; I Gueit; M Delbarre; G Humbert; H Courtois
Journal:  J Mal Vasc       Date:  1997-03

10.  Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus.

Authors:  R Misiani; P Bellavita; D Fenili; O Vicari; D Marchesi; P L Sironi; P Zilio; A Vernocchi; M Massazza; G Vendramin
Journal:  N Engl J Med       Date:  1994-03-17       Impact factor: 91.245

View more
  5 in total

Review 1.  Carnitine Palmitoyl Transferase Deficiency in a University Immunology Practice.

Authors:  Kiley Bax; Paul J Isackson; Molly Moore; Julian L Ambrus
Journal:  Curr Rheumatol Rep       Date:  2020-02-14       Impact factor: 4.592

Review 2.  Indications for biotherapy in systemic vasculitides.

Authors:  Loïc Guillevin; Christian Pagnoux; Philippe Guilpain; Boris Bienvenu; Valérie Martinez; Luc Mouthon
Journal:  Clin Rev Allergy Immunol       Date:  2007-02       Impact factor: 10.817

3.  Metabolic myopathy presenting with polyarteritis nodosa: a case report.

Authors:  Sahana Vishwanath; Mishal Abdullah; Amro Elbalkhi; Julian L Ambrus
Journal:  J Med Case Rep       Date:  2011-06-30

4.  A novel strain of cynomolgus macaque cytomegalovirus: implications for host-virus co-evolution.

Authors:  Justen N Hoffman Russell; Angie K Marsh; David O Willer; Aruna P N Ambagala; Misko Dzamba; Jacqueline K Chan; Richard Pilon; Jocelyn Fournier; Michael Brudno; Joseph M Antony; Paul Sandstrom; Ben J Evans; Kelly S MacDonald
Journal:  BMC Genomics       Date:  2016-04-05       Impact factor: 3.969

Review 5.  Infection and vasculitis.

Authors:  Cristina C Belizna; Mohamed A Hamidou; Hervé Levesque; Loic Guillevin; Yehuda Shoenfeld
Journal:  Rheumatology (Oxford)       Date:  2009-03-03       Impact factor: 7.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.